Cost-effectiveness of multi-drug regimen of amlodipine plus atorvastatin based on the anglo-scandinavian cardiac outcomes trial (ASCOT):: An economic sub-analysis

被引：0

作者：

Koren, Michael

Lindgren, Peter

Buxton, Martin

Kahan, Thomas

Poulter, Neil

Dahlof, Bjorn

Sever, Peter

Wedel, Hans

Tang, Simon S.

Jonsson, Bengt

机构：

[1] Jacksonville Ctr Clin Res, Jacksonville, FL USA

[2] European Hlth Econ, Stockholm, Sweden

[3] Brunel Univ, London, England

[4] Karolinska Inst, Stockholm, Sweden

[5] Imperial Coll, London, England

[6] Sahlgrens Univ Hosp, Gothenburg, Sweden

[7] Nordic Sch Publ Hlth, Gothenburg, Sweden

[8] Pfizer Inc, New York, NY USA

来源：

CIRCULATION | 2007年 / 115卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E568 / E568

页数：1

共 30 条

[1] Amlodipine plus atorvastatin is cost-effective compared to atenolol plus atorvastatin, amlodipine or atenolol alone: The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Lindgren, P.
Buxton, M.
Kahan, T.
Poulter, N.
Dahlof, B.
Sever, P. S.
Wedel, H.
Jonsson, B.
EUROPEAN HEART JOURNAL, 2007, 28 : 857 - 857
[2] Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events:: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm (ASCOT-LLA)
Lindgren, P
Buxton, M
Kahan, T
Poulter, NR
Dahlöf, B
Sever, PS
Wedel, H
Jönsson, B
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2005, 12 (01): : 29 - 36
[3] Health economics of prevention of coronary heart disease and vascular events:: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Jönsson, B
Buxton, M
Hertzman, P
Kahan, T
Poulter, N
JOURNAL OF HUMAN HYPERTENSION, 2001, 15 (Suppl 1) : S53 - S56
[4] Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
B Jönsson
M Buxton
P Hertzman
T Kahan
N Poulter
Journal of Human Hypertension, 2001, 15 : S53 - S56
[5] An amlodipine-based regimen is cost-effective compared to an atenolol-based regimen:: Results from the Anglo-Scandinavian cardiac outcomes trial
Lindgren, P.
Buxton, M.
Kahan, T.
Poulter, N. R.
Dahlof, B.
Sever, P. S.
Wedel, H.
Jonsson, B.
JOURNAL OF HYPERTENSION, 2007, 25 : S137 - S137
[6] Economic evaluation of the anglo-Scandinavian cardiac outcomes trial (ASCOT)-blood pressure lowering arm (BPLA):: A sub-study on incremental cost-effectiveness of amlodipine-based regimen vs. atenolol-based regimen in primary prevention among hypertensive patients with additional risk factors
Lindgren, Peter
Tang, Simon
Buxton, Martin
Kahan, Thomas
Poulter, Neil
Dahlof, Bjorn
Sever, Peter
Wedel, Hans
Buch, Jan
Jonsson, Bengt
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 392A - 392A
[7] Impact of Lifestyle Changes During Five Years of Drug Treatment in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Collier, David J.
Stride, Timothy J.
He, Sophie
Wilson, Sarah L.
Shiel, Julian I.
Caulfield, Mark J.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A215 - A215
[8] Anglo-Scandinavian Cardiac Outcomes Trial - ASCOT - Main protocol summary and sub-study protocols - Editor's note
O'Brien, E
JOURNAL OF HUMAN HYPERTENSION, 2001, 15 : S1 - S1
[9] Prevention of coronary and stroke events with atorvastatin in hypertensive patients - ASCOT-LLA (the Anglo-Scandinavian cardiac outcomes trial - Lipid lowering arm)
Lyakishev, AA
KARDIOLOGIYA, 2003, 43 (05) : 75 - 75
[10] The Economic Consequences of Non-Adherence to Lipid-Lowering Therapy: Results From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Lindgren, Peter
Eriksson, Jennifer
Buxton, Martin
Kahan, Thomas
Poulter, Neil R.
Dahlof, Bjorn
Sever, Peter S.
Wedel, Hans
Jonsson, Bengt
CIRCULATION, 2009, 120 (18) : S484 - S485

← 1 2 3 →